SCHEMBL1469102

SCHEMBL1469102

CCO[Si](OCC)(OCC)C(CC)CCOCC1CCO1

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 1/20 0.33
PDK1 Q15118 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1005637 0.82 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1TDP1TSHRPDK1
SCHEMBL27816552 0.72 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1TDP1TSHRPDK1
SCHEMBL28377554 0.72 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1TDP1TSHRPDK1
SCHEMBL5598454 0.72 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1TDP1TSHR
SCHEMBL18420005 0.72 EPHX1 (0.31)
SCHEMBL8096575 0.72 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1TDP1TSHRPDK1
SCHEMBL27985998 0.72 SMN1; SMN2 (0.33) SMN1; SMN2ALDH1A1TDP1
SCHEMBL12079083 0.71 LMNA (0.37) SMN1; SMN2ALDH1A1TDP1TSHRPDK1
SCHEMBL28292332 0.71 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1TDP1TSHRPDK1
SCHEMBL13301287 0.70 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1TDP1TSHRPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986923-B2 Aqueous base-developable negative-tone films based on functionalized norbornene polymers PROMERUS, LLC (US) 2015-03-24 US claimed
US-20140038112-A1 AQUEOUS BASE-DEVELOPABLE NEGATIVE-TONE FILMS BASED ON FUNCTIONALIZED NORBORNENE POLYMERS PROMERUS, LLC (US) 2014-02-06 US claimed
US-8580477-B2 Aqueous base-developable negative-tone films based on functionalized norbornene polymers PROMERUS LLC (US) 2013-11-12 US claimed
US-20110070543-A1 Aqueous Base-Developable Negative-Tone Films Based On Functionalized Norbornene Polymers PROMERUS LLC (US) 2011-03-24 US claimed
EP-3883745-A1 PRECISION SYSTEM FOR ADDITIVE FABRICATION Inkbit, LLC (US) 2021-09-29 EP disclosed
WO-2020123479-A1 PRECISION SYSTEM FOR ADDITIVE FABRICATION Inkbit, LLC (US) 2020-06-18 WO disclosed
US-8986923-B2 Aqueous base-developable negative-tone films based on functionalized norbornene polymers PROMERUS, LLC (US) 2015-03-24 US disclosed
US-20140038112-A1 AQUEOUS BASE-DEVELOPABLE NEGATIVE-TONE FILMS BASED ON FUNCTIONALIZED NORBORNENE POLYMERS PROMERUS, LLC (US) 2014-02-06 US disclosed
US-8580477-B2 Aqueous base-developable negative-tone films based on functionalized norbornene polymers PROMERUS LLC (US) 2013-11-12 US disclosed
US-20110070543-A1 Aqueous Base-Developable Negative-Tone Films Based On Functionalized Norbornene Polymers PROMERUS LLC (US) 2011-03-24 US disclosed
US-6838515-B2 Process for the preparation of esters of (meth)acrylic acid DSM IP ASSETS B.V. (NL) 2005-01-04 US disclosed
US-6714712-B2 URETHANE-FREE POLYESTER ACRYLATE OLIGOMERS HAVE ALSO BEEN USED IN RADIATION-CURABLE COATING COMPOSITIONS FOR OPTICAL GLASS FIBERS DSM N.V. (NL) 2004-03-30 US disclosed
EP-1385893-A2 RADIATION CURABLE COATING COMPOSITION DSM IP Assets B.V. (NL) 2004-02-04 EP disclosed
EP-1353893-A1 PROCESS FOR THE PREPARATION OF ESTERS OF (METH)ACRYLIC ACID Dsm N.V. (NL) 2003-10-22 EP disclosed
US-20020168164-A1 Radiation curable coating composition DSM IP ASSETS B.V. (NL) 2002-11-14 US disclosed
US-20020156317-A1 Process for the preparation of esters of (meth)acrylic acid DSM IP ASSETS B.V. (NL) 2002-10-24 US disclosed
WO-2002055574-A2 RADIATION CURABLE COATING COMPOSITION DSM NV (NL) 2002-07-18 WO disclosed
WO-2002055473-A1 PROCESS FOR THE PREPARATION OF ESTERS OF (METH)ACRYLIC ACID DSM IP ASSETS B.V. (NL) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156317-A1 Process for the preparation of esters of (meth)acrylic acid ADH1A, PAM, OXGR1 SMN1; SMN2 3788/4885ALDH1A1 181/4885TDP1 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.